STOCK TITAN

HIMS insider sells vested stock; prior 60,000-share sale raised $3.21M

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Hims & Hers Health, Inc. reported a proposed insider sale under Rule 144: 10,021 Class A shares are planned for sale through Fidelity Brokerage, with an aggregate market value of $506,060.50 and an approximate sale date of 09/17/2025 on the NYSE. The shares were acquired by restricted stock vesting from the issuer on 09/15/2025 as compensation.

The filing also discloses a recent disposition by the same person, Patrick H. Carroll, who sold 60,000 Class A shares on 08/06/2025 for gross proceeds of $3,214,880.58. The filer certifies they are not aware of any undisclosed material adverse information about the issuer.

Positive

  • Transaction is a result of restricted stock vesting, indicating the shares were granted as compensation rather than purchased opportunistically
  • Sale will be executed through a registered broker (Fidelity), suggesting standard market procedures and transparency

Negative

  • Recent insider selling activity includes a prior disposal of 60,000 shares for $3,214,880.58, which may indicate notable insider liquidity
  • Aggregate market value of the planned sale ($506,060.50) represents immediate insider monetization that investors may view as supply pressure

Insights

TL;DR: Insider plans to sell vested compensation shares (10,021 shares, ~$506k); prior large sale of 60,000 shares occurred in August.

The proposed sale reflects routine monetization of recently vested restricted stock rather than an open-market issuance. The size of the proposed sale (10,021 shares, $506k) is small relative to typical public float levels for a listed issuer, though materiality depends on total outstanding float not provided here. The disclosure of a prior sale of 60,000 shares for $3.21M is relevant for monitoring insider selling trends. No additional financial metrics or company operational details are included in this filing.

TL;DR: Transaction appears to be compensation vesting followed by planned sale; disclosure aligns with Rule 144 requirements.

The filing documents that the securities were acquired via restricted stock vesting and the intended sale is executed through a brokerage firm, indicating standard compliance with resale rules. The signer’s representation that they have no undisclosed material information is customary and required. Absent other governance disclosures, this notice signals routine insider liquidity rather than governance concerns, though continued insider sales could warrant investor attention if they persist.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What shares is HIMS insider planning to sell?

The filer plans to sell 10,021 Class A shares through Fidelity Brokerage with an aggregate market value of $506,060.50.

When were the shares acquired that are being sold under Rule 144?

The shares were acquired on 09/15/2025 via restricted stock vesting and payment was recorded as compensation.

Has the seller made recent sales of HIMS stock?

Yes. Patrick H. Carroll sold 60,000 Class A shares on 08/06/2025 for gross proceeds of $3,214,880.58.

Through which exchange and broker will the sale occur?

The planned sale is listed as occurring on the NYSE through Fidelity Brokerage Services LLC.

Does the filer assert possession of undisclosed material information?

By signing the notice, the filer represents they do not know any undisclosed material adverse information regarding the issuer.
Hims & Hers Health Inc

NYSE:HIMS

HIMS Rankings

HIMS Latest News

HIMS Latest SEC Filings

HIMS Stock Data

3.92B
204.96M
10.63%
88.99%
33.02%
Household & Personal Products
Services-offices & Clinics of Doctors of Medicine
Link
United States
SAN FRANCISCO